Axsome Therapeutics,Inc. (NASDAQ:AXSM) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07. Submission of Matters to a Vote of Security
Holders.

At the 2017 annual meeting of stockholders (the Annual Meeting)
of Axsome Therapeutics,Inc. (the Company) held on June2, 2017,
the following proposals were submitted to the stockholders of the
Company:

Proposal1: The election of one director to serve as a ClassII
director until the Companys 2020 annual meeting of stockholders
and until his successor is duly elected and qualified.

Proposal2: The ratification of the appointment of Ernst Young LLP
as the Companys independent registered public accounting firm for
the fiscal year ending December31, 2017.

For more information about the foregoing proposals, see the
Companys definitive proxy statement on Schedule 14A filed with
the United States Securities and Exchange Commission on May2,
2017 (the Proxy Statement). Of the 23,593,667 shares of the
Companys common stock entitled to vote at the Annual Meeting,
20,139,864 shares, or approximately 85%, were represented at the
meeting in person or by proxy, constituting a quorum. The number
of votes cast for, against or withheld, as well as abstentions
and broker non-votes, if applicable, in respect of each such
proposal is set forth below:

Proposal1: Election of ClassII Director.

The Companys stockholders elected the following director to serve
as a ClassII director until the 2020 annual meeting of
stockholders and until his successor is duly elected and
qualified. The votes regarding the election of the director were
as follows:

The Companys stockholders ratified the appointment of Ernst Young
LLP as the Companys independent registered public accounting firm
for the fiscal year ending December31, 2017. The votes regarding
this proposal were as follows:

About Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer’s disease (AD).

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Recent Trading Information

Axsome Therapeutics, Inc. (NASDAQ:AXSM) closed its last trading session up +0.05 at 4.10 with 132,938 shares trading hands.